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LIVER DISEASE
Selective plasma filtration for treatment of fulminant
hepatic failure induced by D-galactosamine in a pig
model
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Background: Plasma exchange may be useful for treating patients with fulminant hepatic failure but
during the procedure growth factors that are important for hepatic regeneration are discarded. Addi-
tion of a selective plasma filter to the plasmapheresis circuit could eliminate protein bound toxic sub-
stances and retain growth factors for hepatic regeneration. This process is called selective plasma
filtration.
Aims: To determine if selective plasma filtration could be a useful treatment modality for fulminant
hepatic failure.
Methods: The system was tested in five groups of pigs with fulminant hepatic failure induced by galac-
tosamine: group I, diseased control group (n=5); group II, sham control, (n=6); group III, plasma
exchange (n=6); group IV, treatment with AC-1770 selective plasma filter (n=7); and group V, treat-
ment with AC-1730 selective plasma filter which had a smaller pore size than AC-1770 (n=7). Fresh
pig plasma was given to replace filtered plasma in pigs of groups III, IV, and V. Treatment was initi-
ated 48 hours after administration of 0.75 g/kg galactosamine. The efficacy of selective plasma filtra-
tion was assessed by survival rate and improvement in haematological, biochemical, and
immunohistological parameters.
Results: Pigs treated with AC-1770 or AC-1730 selective plasma filters survived longer than the other
groups (group I: 55 (10) hours; group II: 68 (7) hours; group III: 91 (10) hours; group IV: 269 (156)
hours; group V: 950 (555) hours). One pig in group IV survived for 50 days; one pig in group V sur-
vived for 77 days and another pig in group V is still alive (>150 days). After treatment, plasma levels
of aspartate aminotransferase, bilirubin, bile acid, ammonia, lactate dehydrogenase, and
α-glutathione-S-transferase decreased. Substantial amounts of tumour necrosis factor α (TNF-α) and
endotoxin were found in the filtrate. The selective plasma filtration groups retained significantly higher
amounts of hepatocyte growth factor than plasma exchange alone. Similar TNF-α clearance was
observed in the selective plasma filtration groups and the plasma exchange group. On day 4, signifi-
cant improvement in liver function, as measured by the indocyanine green clearance test, was
observed in groups IV and V but not in the other groups. A higher regeneration index of hepatocytes
was also observed in the groups treated with AC-1770 and AC-1730 selective plasma filters.
Conclusion: Selective plasma filtration improved survival time and expedited liver regeneration in pigs
with fulminant hepatic failure.
Fulminant hepatic failure is associated with a mortalityrate of 82–97% if liver transplantation is not available.1 2Many putative toxins which have accumulated in the
body as a result of liver impairment and cytokines released
directly from the necrotic liver into the circulation are thought
to be responsible for deterioration in the condition of the
patient.3 The necrotic liver may elicit a pan-inflammatory
response manifested as fever, vasodilatation, hypotension,
adult respiratory distress syndrome, and eventually multior-
gan failure leading to death. The presence of these undesirable
cytokines and toxic substances may also be responsible for
inhibition of hepatic regeneration in fulminant hepatic
failure.4 Liver transplantation remains the best treatment for
fulminant hepatic failure because the necrotic liver that elicits
the cytokine response is removed and a new liver providing all
the essential functions is in place. However, liver graft is not
readily available and the “golden” period for liver transplanta-
tion is generally short. Management of patients with
fulminant hepatic failure therefore aims at stabilising the
patient until a suitable donor is available. The use of porcine
hepatocytes in an extracoporeal system appears promising5–7
but none has been adopted clinically. Plasma exchange has
been found to be useful in treating patients with fulminant
hepatic failure8 by removal of hepatic toxins and replacement
of clotting factors. However, its major disadvantage is loss of
substances from plasma that may promote hepatic
regeneration.9 The components in plasma can be separated
according to their size using a selective plasma filter. This
process is called selective plasma filtration. In this process,
protein bound toxins are filtered while useful macromolecules
such as hepatocyte growth factor (HGF) are retained. We
hypothesised that the introduction of a selective plasma filter
in the plasma exchange circuit could be used as a liver detoxi-
fying device. In this paper, we present results of an application
of this system to treat pigs with fulminant hepatic failure
induced by D-galactosamine.
MATERIALS AND METHODS
Animal model of hepatic failure
We used a porcine model of galactosamine induced fulminant
hepatic failure that was previously studied in our laboratory.10
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Female inbred LargeWhite pigs,weighing 17–28 kg and 10–15
weeks old, were obtained from the Pig Breeding Centre, the
Government of Hong Kong, SAR. Animals were housed in a
climate controlled (21°C) room. They were quarantined and
allowed to acclimatise in the animal facility for a minimum of
one week before being used in this study. All animals were
given a standard laboratory diet and water ad labium until the
time of D-galactosamine injection. Pigs were initially anaes-
thetised with ketamine hydrochloride (15 mg/kg) and placed
on a mechanical ventilator and anaesthesia machine for con-
tinuous administration of isoflurane. The right jugular vein
was exposed and cannulated with a 16 G cannula for blood
sampling, or drug or fluid administration. The indocyanine
green (ICG) clearance test was performed by administering
0.5 mg/kg of ICG intravenously and blood samples were
obtained at five minute intervals for 20 minutes to determine
ICG clearance. D-Galactosamine (Research Organics Inc,
Cleveland, Ohio, USA) 0.75 g/kg was dissolved in 5% dextrose
in water and adjusted to pH 6.8 with 1 mol/l NaOH. The solu-
tion was then sterilised and used immediately. After adminis-
tration of galactosamine, pigs were allowed to wake up from
general anaesthesia and left in the cage. Only sedation was
used for blood sampling in the subsequent days and between
treatment sessions.
Five different groups of animals were studied.
Group I: Diseased control group (n=5). Pigs received a bolus
infusion of 0.75 g/kg galactosamine. No further treatment was
given.
Group II: Sham control group (n=6). Pigs received a bolus
infusion of 0.75 g/kg galactosamine. Forty eight hours later,
pigs were connected to the plasma separator without a
secondary selective plasma filter for the same duration as
groups III, IV, and V. Its own blood cells and plasma were then
completely returned to the blood circulation without any sub-
stitution of fresh pig plasma.
Group III: Plasma exchange group (n=6). Pigs received a
bolus injection of 0.75 g/kg galactosamine. Forty eight hours
later, they were connected to the extracorporeal system of
plasmapheresis. Filtered plasma was replaced by fresh pig
plasma.
Group IV: AC-1770 group (n=7). Pigs received the same treat-
ment as group III but a selective plasma filter (Cascadeflo
AC-1770; Asahi Medical, Tokyo, Japan) was added to the
circuit. Filtered plasma was replaced by fresh pig plasma.
Group V: AC-1730 group (n=7). Pigs received the same treat-
ment as groups III and IV but a selective plasma filter of
smaller pore size than AC-1770 (Cascadeflo AC-1730; Asahi
Medical) was used.
Extracoporeal circuit of the plasmapheresis and
selective plasma filtration
Forty eight hours after administration of galactosamine, all pigs,
except the diseased control group, underwent their respective
treatments. Pigs were anaesthetised and placed on amechanical
ventilator and anaesthesia was maintained by inhalation of
0.5–1.5% isoflurane and a 1:3 ratio of oxygen and nitrous oxide.
Prior to treatment, blood sampling and the ICG clearance test
were performed. The plasma filter (PF 2000N; Gambro,
Germany) and the selective plasma filters were washed and
primed according to the manufacturer’s instructions. After can-
nulation of the external iliac artery and vein, the blood of the
pigs was passed through a plasma separation system (PEM 10;
Gambro, Lund, Sweden) at a mean flow rate of 120 ml/min.
Heparin (250 U/h) was administered as necessary to avoid clot-
ting in the extracorporeal circuit. Plasma separated from blood
at a rate of 20 ml/min (fig 1). Plasma then passed through the
selective plasma filter in which plasma components were sepa-
rated according to their size. The filtrate with a flow rate of 10
ml/min was passed into the waste bag and discarded. The
amount of filtrate removed was replaced by the same volume of
fresh pig plasma. The retained plasma, substituted plasma, and
Figure 1 Diagrammatic
representation of the arrangement of
the plasmapheresis and selective
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Figure 2 Survival rates of groups I–V. *p<0.05 versus diseased
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original blood cell components were reconstituted and returned
to the animal via the venous cannula. The treatment lasted for
four hours and approximately 2 litres of plasma were removed
from each pigs in groups III, IV, and V. A second treatment ses-
sion was initiated two days after the first treatment if systolic
blood pressurewas greater than 80mmHg.Pigswere taken care
of and monitored closely by an experienced veterinary
technician.
Clinical data were recorded hourly. Blood was collected
before and after treatment for renal and liver biochemistry
determinations. Plasma levels of ammonia, lactate, bile acid,
tumour necrosis factor α (TNF-α), endotoxin, and HGF were
also measured. Plasma TNF-α was assayed by an in vitro
ELISA method (Endogen Inc., Massachusetts, USA). TNF-α
clearance was calculated using the following equation:
SC=Cf/Cp
Cl (ml/min)=SC×Qf
where Cf is TNF-α in the filtrate and Cp is TNF-α in plasma
before treatment, SC is the sieving coefficient, Qf is the filtra-
tion flow rate, and Cl is TNF-α clearance.
Plasma endotoxin was measured using a limulus amoebo-
cyte lysate pyrochrome kit (Associates of Cape Cod, Massa-
chusetts, USA). Plasma was diluted and heated at 60°C for 30
minutes prior to the assay. As there was cross reactivity
between porcine HGF and monoclonal antibody against
human HGF,11 porcine HGF was assayed using a commercially
available ELISA kit (R&D Systems, Minneapolis, USA).
Percentage HGF retention was used to compare the amount of
Table 1 Laboratory values in group I (diseased control)
Parameter 0 h 24 h 48 h
Sodium (mmol/l) 135 (2) 141 (3) 142 (2)
Potassium (mmol/l) 3.5 (0.1) 4.1 (0.1) 3.7 (0.2)
Calcium (mmol/l) 2.52 (0.08) 2.66 (0.08) 2.34 (0.13)
Protein (g/l) 56 (2) 64 (2) 61 (2)
Total bilirubin (µmol/l) 3 (1) 37 (4)*** 73 (4)***
Alkaline phosphatase (U/l) 143 (17) 425 (64)** 1048 (127)***
Aspartate aminotransferase (U/l) 42 (5) 1568 (767) 2753 (1070)*
Lactate dehydrogenase (U/l) 1107 (117) 3814 (1010)* 7475 (1226)***
Ammonia (µg/dl) 92 (30) 133 (55) 565 (251)*
Bile acid (µmol/l) 16 (7) 479 (19)*** 358 (23)***
Lactate (mmol/l) 14 (2) 37 (10) 52 (12)*
TNF-α (pg/ml) 70 (2) 76 (3) 103 (13)**
Endotoxin (EU/ml) 1.59 (0.30) 3.98 (1.30) 5.30 (1.69)*
Platelet (103/µl) 289 (39) — 214 (90)
Activated clotting time (s) 129 (8) 163 (11) 205 (5)**
ICG at 15 min (%) 17 (3) — 57 (5)***
Data are mean (SEM).
ICG, indocyanine green; TNF-α, tumour necrosis factor α.
*p<0.05, **p<0.01, ***p<0.001 versus 0 h (time of galactosamine injection).
Table 2 Comparison of liver enzymes in groups II–V
Parameter Sham control Plasma exchange AC-1770 AC-1730
Alkaline phosphatase (U/l)
Day 0 96 (21) 154 (29) 141 (17) 154 (30)
Day 1 281 (42) 381 (67) 363 (42) 373 (44)
Pre-T 600 (72) 614 (197) 702 (71) 609 (96)
Post-T 513 (103) 246 (43) 269 (16)*** 366 (49)
Filtrate — 395 (91) 237 (30) 72 (16)
Day 3 725 (127) 856 (199) 664 (97) 671 (202)
Aspartate aminotransferase (U/l)
Day 0 52 (9) 26 (5) 47 (9) 45 (7)
Day 1 498 (154) 716 (557) 1396 (909) 818 (392)
Pre-T 2875 (976) 2605 (989) 3680 (632) 1387 (421)
Post-T 1812 (458) 673 (169)* 958 (243)*** 472 (171)*
Filtrate — 1259 (425) 1006 (289) 433 (151)
Day 3 3047 (1317) 1159 (225) 1580 (662)* 1108 (675)
Lactate dehydrogenase (U/l)
Day 0 1176 (225) 953 (109) 1222 (278) 1310 (162)
Day 1 2641 (649) 2323 (836) 2889 (628) 1948 (227)
Pre-T 7090 (1550) 8657 (1944) 8400 (1351) 4704 (755)
Post-T 5298 (1022) 2474 (341)*** 2298 (549)*** 2460 (249)*
Filtrate — 3382 (846) 2506 (795) 988 (123)
Day 3 7770 (1128) 8200 (895) 4406 (1069)** 5886 (1427)
α-Glutathione S-transferase (µg/l)
Day 0 17 (7) 10 (4) 21 (12) 6 (3)
Day 1 21 (9) 201 (166) 35 (10) 49 (24)
Pre-T 130 (44) 282 (147) 235 (73) 126 (34)
Post-T 88 (23) 83 (18) 108 (38) 47 (9)
Filtrate — 81 (22) 122 (39) 64 (13)
Day 3 129 (46) 106 (49) 89 (6) 125 (29)
Data are mean (SEM).
Pre-T, before treatment; Post-T, after treatment.
*p<0.05, **p<0.01, ***p<0.001 versus pretreatment.
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HGF remaining after treatment between the selective plasma
filtration groups and the plasma exchange group, and was
calculated using the formula:
%HGF=Ct/Ci×100
where Ct is the concentration of HGF (pg/ml) after the
treatment and Ci is the concentration of HGF (pg/ml) before
treatment.
Hepatocyte proliferation activity was compared between
groups III, IV, and V after their respective treatments by detec-
tion of Ki-67 protein in liver using the immunohistochemical
staining method. Liver tissue was taken from a normal pig
(acting as a control) and pigs from each group at postmortem
examination with comparable survival times. The Ki-67 anti-
human monoclonal antibody B56 (PharMingen, Cat No
36215A), shown to cross react with porcine Ki-67, was used.
Counting of Ki-67 positive cells was done by two independent
observers for at least 1000 cells using an image analyser
(MetaMorph Imaging System; Universal Imaging Corpora-
tion, Pennsylvania, USA).Hepatocyte proliferative activity was
expressed as labelling index, which was defined as the ratio of
the number of positive Ki-67 hepatocytes to the total number
of hepatocytes counted.
The study was approved by the Committee of Use of Live
Animals for Study and Research of the University of Hong
Kong.
Statistical analysis
Data are expressed as mean (SEM) and were analysed using
the software Instat and Prism 3 (GraphPad Software Inc.,
California, USA). Sample size was estimated and calculated by
Statmate (GraphPad Software Inc.) with the input of SD of 19
hours for the survival time of pigs treated with galactosamine
from the pilot experiments, and an α value of 0.05 (the
threshold p value). A sample size of seven was chosen for the
selective plasma filtration groups after balancing the cost of
the experiments and the statistical factors. Survival time was
defined as the duration between administration of galactos-
amine and death of the pig. Survival curves were computed
using the Kaplan-Meier method for the different groups and
compared using the log rank test. An animal surviving for four
days after galactosamine administration was considered a
survivor and this definition was used to determine the
mortality rate among the groups. Blood biochemical param-
eters between the treatment groups were analysed using one
way ANOVA and the t test for multiple comparisons. Fisher’s
test was used to compare mortality rates. A p value <0.05 was
considered significant.
Table 3 Comparison of biochemical parameters in groups II–V
Parameter Sham control Plasma exchange AC-1770 AC-1730
Total bilirubin (µmol/l)
Day 0 2 (1) 2 (1) 3 (1) 2 (1)
Day 1 20 (5) 33 (8) 32 (3) 31 (8)
Pre-T 48 (5) 61 (11) 60 (6) 52 (5)
Post-T 43 (3) 29 (7)* 24 (6)*** 26 (5)**
Filtrate — 37 (6) 27 (6) 19 (4)
Day 3 100 (13)*** 94 (19) 80 (12) 76 (6)
Bile acid (µmol/l)
Day 0 5 (1) 6 (1) 5 (1) 6 (2)
Day 1 367 (15) 378 (21) 376 (35) 365 (42)
Pre-T 339 (12) 347 (31) 336 (28) 330 (34)
Post-T 283 (25) 218 (31)** 155 (14)*** 181 (37)**
Filtrate — 251 (26) 166 (10) 147 (21)
Day 3 254 (49) 236 (30)* 219 (33)** 282 (8)
Ammonia (µg/dl)
Day 0 93 (9) 79 (9) 80 (25) 85 (25)
Day 1 159 (30) 210 (93) 109 (28) 156 (45)
Pre-T 406 (104) 475 (142) 318 (50) 242 (34)
Post-T 408 (89) 570 (381) 215 (61) 120 (18)
Filtrate — 531 (293) 256 (64) 173 (50)
Day 3 868 (297)* 475 (101) 289 (84) 358 (86)
Lactate (mg/dl)
Day 0 13 (2) 14 (1) 15 (3) 10 (1)
Day 1 20 (4) 25 (5) 14 (2) 19 (2)
Pre-T 44 (11) 45 (9) 37 (9) 37 (6)
Post-T 38 (17) 52 (21) 47 (16) 22 (4)
Filtrate — 42 (10) 39 (11) 26 (4)
Day 3 30 (8) 31 (14) 25 (9) 19 (5)*
TNF-α (ρg/ml)
Day 0 63 (4) 71 (16) 57 (5) 47 (9)
Day 1 81 (16) 75 (26) 66 (6) 54 (13)
Pre-T 68 (5) 105 (28) 93 (11) 65 (10)
Post-T 71 (5) 91 (33) 71 (8) 82 (18)
Filtrate — 89 (21) 68 (5) 67 (10)
Day 3 73 (5) 89 (23) 73 (9) 64 (7)
Endotoxin (EU/ml)
Day 0 1.85 (0.29) 2.10 (0.14) 2.07 (0.23) 1.49 (0.23)
Day 1 2.18 (0.21) 3.82 (0.49) 2.20 (0.35) 1.70 (0.35)
Pre-T 4.20 (0.98) 4.52 (1.18) 5.18 (1.56) 3.05 (0.47)
Post-T 4.83 (1.32) 2.76 (0.76) 4.10 (0.49) 1.86 (0.22)
Filtrate — 3.21 (0.59) 2.60 (0.64) 2.40 (0.58)
Day 3 7.73 (2.83) 4.38 (1.46) 4.16 (1.16) 3.33 (1.54)
Data are mean (SEM).
Pre-T, before treatment; Post-T, after treatment; TNF-α, tumour necrosis factor α.
*p<0.05, **p<0.01, ***p<0.001 versus pretreatment.
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RESULTS
Laboratory data and survival of the diseased control
group
All pigs recovered consciousness from general anaesthesia
within one hour after administration of D-galactosamine. Ini-
tially, they walked spontaneously around in the cage and
drank water. They were still alert 24 hours after drug admin-
istration but after 48 hours they went through a state of
increasing drowsiness, somnolence, and eventually coma
before death.
All pigs in the diseased control group died within 83 hours
and mean survival time was 55 hours (fig 2). A progressive
increase in levels of liver enzymes, bilirubin, bile acid, and
ammonia indicated liver injuries at 24 hours after administra-
tion of galactosamine, and these levels remained increased
throughout the experiment (table 1). Coagulopathy was
manifest as a decrease in platelet count and elevation of acti-
vated clotting time (table 1). Liver function impairment was
reflected by a gradual increase in ICG retention value at 15
minutes from 17 (3)% on day 0 to 57 (5)% on day 2 (table 1).
Plasma TNF-α and endotoxin levels were also elevated signifi-
cantly compared with day 0 (table 1).
As mean survival time of the diseased control group was 55
hours (fig 2), and the general condition of the pigs and
biochemical and haematological parameters deteriorated
abruptly after 48 hours of galactosamine infusion, selective
plasma filtration was initiated at 48 hours to test the efficacy
of the system.
Survival of groups II– V
None of the pigs in the sham control or plasma exchange
groups survived for more than five days. Five pigs in the
Table 4 Comparison of biochemical and haematological parameters in groups II–V
Parameter Sham control Plasma exchange AC-1770 AC-1730
Sodium (mmol/l)
Day 0 136 (1) 139 (1) 135 (2) 137 (1)
Day 1 139 (3) 140 (2) 145 (1) 140 (2)
Pre-T 140 (1) 135 (2) 136 (2) 135 (2)
Post-T 135 (5) 138 (1) 137 (2) 136 (2)
Filtrate — 135 (3) 133 (4) 140 (2)
Day 3 145 (1) 142 (2) 144 (3) 139 (2)
Potassium (mmol/l)
Day 0 3.7 (0.2) 3.7 (0.2) 3.6 (0.1) 3.4 (0.1)
Day 1 3.7 (0.2) 3.8 (0.3) 3.9 (0.2) 3.9 (0.1)
Pre-T 3.6 (0.3) 3.7 (0.3) 3.5 (0.1) 3.4 (0.1)
Post-T 3.8 (0.2) 3.6 (0.4) 3.7 (0.1) 3.6 (0.1)
Filtrate — 3.6 (0.4) 3.0 (0.1) 2.8 (0.1)
Day 3 3.7 (0.1) 3.6 (0.2) 3.5 (0.2) 3.2 (0.2)
Calcium (mmol/l)
Day 0 2.41 (0.05) 2.44 (0.03) 2.46 (0.09) 2.51 (0.04)
Day 1 2.48 (0.10) 2.60 (0.06) 2.67 (0.06) 2.63 (0.08)
Pre-T 2.49 (0.08) 2.49 (0.10) 2.43 (0.08) 2.46 (0.05)
Post-T 2.33 (0.09) 2.44 (0.09) 2.29 (0.12) 2.21 (0.20)
Filtrate — 2.35 (0.08) 1.92 (0.16) 2.00 (0.13)
Day 3 2.35 (0.12) 2.45 (0.12) 2.34 (0.13) 2.42 (0.06)
Protein (g/l)
Day 0 63 (5) 54 (2) 56 (2) 59 (2)
Day 1 60 (8) 55 (6) 69 (6) 69 (5)
Pre-T 51 (8) 47 (3) 53 (4) 54 (5)
Post-T 39 (7) 33 (3)* 36 (2)** 40 (3)*
Filtrate — 32 (3)†† 25 (2)† 17 (1)
Day 3 45 (3) 43 (3) 44 (4) 50 (3)
Platelet (103/µl)
Day 0 327 (38) 307 (28) 285 (50) 296 (28)
Pre-T 196 (57) 224 (64) 156 (36) 207 (29)
Post-T 183 (51) 213 (55) 150 (31) 169 (30)
Activated clotting time (s)
Day 0 136 (6) 136 (21) 128 (10) 119 (11)
Day 1 185 (12) 180 (11) 224 (35) 148 (6)
Pre-T 540 (178) 478 (166) 464 (140) 532 (421)
Post-T 442 (198) 152 (13)* 166 (6)* 152 (8)*
Data are mean (SEM).
Pre-T, before treatment; Post-T, after treatment.
*p<0.05, **p<0.01 versus pretreatment; †p<0.05, ††p<0.01 versus AC-1730.
Table 5 Indocyanine green retention values15min
Disease control Sham control Plasma exchange AC-1770 AC-1730
Day 0 17 (3) 13 (3) 12 (3) 17 (4) 18 (5)
Day 2 57 (5)*** 42 (5)*** 47 (3)*** 58 (3)*** 53 (5)***
Day 4 — — 40 (2) 45 (4)† 37 (3)†
Day 7 — — — 25 26 (1)
Data are mean (SEM).
Day 0 was the time of galactosamine injection.
***p<0.001 versus day 0; †p<0.05 versus day 2. There were no statistically significant differences between
values in all groups on day 2 (p>0.05).
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AC-1770 group and five in the AC-1730 group survived beyond
day 4. Mortality rates in groups AC-1770 and AC-1730 on day
4 were both 29% (five of seven pigs) which were significantly
lower than in the sham control group (100%) (p=0.02,
Fisher’s test). Themortality rate in the plasma exchange group
was 50% (three of six pigs) which was lower than in the sham
control group but was not statistically significant. One pig in
the AC-1770 group survived for 50 days; one in the AC-1730
group survived for 77 days and one in the AC-1730 group is
still alive at the time of preparation of the manuscript (>150
days). The survival curves of all five groups are shown in fig 2.
Three pigs in the AC-1770 group and one pig in the AC-1730
group received the second treatment on day 4. No pig in the
plasma exchange group received the second treatment as they
were seriously ill even though they survived to day 4.
Laboratory data of groups II –V
All pigs in groups II–V exhibited the same abnormalities in
plasma liver enzymes, bilirubin, bile acid, lactate, blood ammo-
nia, ICG retention value, activated clotting time values, and
platelet count as the diseased control animals (tables 2–5).After
the treatments there was a significant reduction in plasma lev-
els of aspartate aminotransferase, lactate dehydrogenase,
bilirubin, and bile acid in groups III–V (tables 2, 3). Plasma lev-
els of alkaline phosphatase, α-glutathione-S-transferase, am-
monia, and endotoxin also decreased although these were not
statistically significant. Substantial amounts of endotoxin,
together with bilirubin, bile acid, ammonia, liver enzymes, and
protein were found in the filtrate (tables 2–4). TNF-α clearance
rates for the AC-1770, AC-1730, and plasma exchange groups
were 8.0 (0.6) ml/min, 10 (0.8) ml/min, and 10 (1.6) ml/min,
respectively, indicating that the removal rates of this proinflam-
matory cytokine were similar in the plasma exchange and
selective plasma filtration groups (p>0.05) (fig 3).
Percentage HGF retentions for the AC-1770, AC-1730, and
plasma exchange groups were 100 (11), 93 (10), and 66 (9),
respectively. This indicated that the selective plasma filtration
groups could retain significantly larger amounts of HGF after
treatment compared with the plasma exchange group
(p<0.05) (fig 4).
On day 3, a rebound increase in plasma levels of bilirubin
were observed in all pigs in groups III–V (table 3). However,
compared with pretreatment values, the increase was not sta-
tistically significant. In contrast, plasma bilirubin levels in the
sham control group were significantly higher than pretreat-
ment values. For plasma bile acid levels, day 3 values in the
AC-1770 and plasma exchange groups were lower than
pretreatment values (p<0.05). A significant decrease in
plasma aspartate aminotransferase and lactate dehydrogenase
on day 3 was observed in the AC-1770 group (p<0.01) but not
in the other groups. Plasma ammonia levels in the AC-1770
and AC-1730 groups appeared lower than the corresponding
values in the sham control and plasma exchange groups. A
marked increase in plasma ammonia was found in the sham
control group (p<0.05).
For groups II–V, there was no major change in plasma
sodium, potassium, or calcium levels after treatment (table 4).
Plasma protein levels in the AC-1770 and plasma exchange
groups were reduced after treatment and concentrations in
the filtrate were higher than those in group AC-1730, indicat-
ing that the pore size of the AC-1730 membrane was more
selective (table 4).
On day 4, a repeat ICG clearance test in the pigs who
survived showed that retention values in the AC-1770 and
AC-1730 treatment groups were significantly lower than those
before treatment (table 5). A similar trend was observed in the
plasma exchange group but the reduction was not statistically
significant.
Measurement of platelet concentrations after treatment
indicated that there was no further reduction in platelet count
after treatment (table 4). Activated clotting time values were
significantly improved in groups III–V probably because fresh
plasma was used in these groups (table 4).
In terms of Ki-67 staining for hepatocyte proliferation
activity, positive staining was not seen in normal liver (fig 5)
Figure 3 Comparison of tumour necrosis factor α (TNF-α)
clearance between the selective plasma filtration groups and the























Figure 4 Comparison of the amount of hepatocyte growth factor
(HGF) retained after treatment between the selective plasma filtration






















Figure 5 Ki-67 immunohistochemical staining of a normal pig liver.
Table 6 Labeling index (LI) (Ki-67) in the liver of pigs
in groups III–V
Group n Survival time (h) LI%
Plasma exchange 4 73–117 20 (1)
AC-1770 4 130–156 32 (3)*
AC-1730 3 82–136 33 (6)*
Data are mean (SEM).
*p<0.05 versus plasma exchange group.
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but was remarkable in pig liver treated by selective plasma fil-
tration. Compared with pigs treated by plasma exchange only,
the labelling index was significantly higher in the groups
treated with the AC-1770 and AC-1730 filters (table 6; figs
6–8).Mean labelling index in the plasma exchange group was
only 20% which was significantly lower than that for the
AC-1770 and AC-1730 groups (32% and 33%, respectively). It
appeared that the higher values of HGF retention in the selec-
tive plasma filtration groups corresponded to their higher
labelling index.
All pigs undergoing treatment procedures remained
haemodyamically stable and urine output was normal. At
postmortem examination, the livers of the pigs were pale,
oedematous, and indurated. Ascites were found and a few
scattered mesenteric haemorrhages were observed in some
pigs. No abnormality was seen in the kidneys or heart. Histo-
logical examination of the liver specimens demonstrated mas-
sive hepatic necrosis.
DISCUSSION
Animal models of fulminant hepatic failure with high
mortality rates as well as the potential for recovery are
required for evaluation of the efficacy of liver supporting
therapeutic devices. Animal models of fulminant hepatic fail-
ure induced by surgical means, including hepatectomy or
complete hepatic ischaemia, are not suitable for this purpose
because there is no potential for reversibility or recovery. In
contrast, a porcine model of fulminant hepatic failure induced
by galactosamine was used in our study because this model
demonstrated high reproducibility and potential
reversibility10 12 which fulfil the majority of the criteria set by
Terblanche and Hickman.13 Moreover, postmortem examina-
tion did not show any damage to organs other than the liver,
supporting the fact that the cause of death in experimental
animals was attributed to liver failure.
In the present study we demonstrated that selective plasma
filtration was efficacious in removing toxic substances which
had accumulated in pigs with fulminant hepatic failure (evi-
denced by a decrease in plasma ammonia, bilirubin, bile acid
levels, etc), halting the progression of liver injury (as shown by
decreased plasma alanine aminotransferase and lactate dehy-
drogenase levels), retaining useful materials (evidenced by
higher HGF retention), improving liver function (as shown by
a better ICG clearance value), promoting liver regeneration,
and prolonging survival of pigs after the onset of fulminant
hepatic failure. The data also indicated that selective plasma
filtration was more effective than plasma exchange alone.
The majority of patients with fulminant hepatic failure will
deteriorate and die after the onset of disease but a few may
recover spontaneously and resume normal liver function.14 15
The occasional survivors had rapid regeneration of the liver,
probably because the initial cause of the liver injury was not
persistent and the accumulated toxic substances that perpetu-
ate liver injury were low in concentration. The exact nature of
the toxic substances that produce liver injury and inhibit liver
regeneration is not known but may include bilirubin, bile acid,
and TNF-α.16 Impairment of hepatic clearance in liver failure
also causes an excessive accumulation of ammonia, mer-
captans, indoles, and gamma amino butyric acid that are
highly associated with hepatic encephalopathy.17 Liver regen-
eration is stimulated by many factors, among which HGF is
the most important.18 High levels of HGF are present in
patients with fulminant hepatic failure.19 Survival of patients
with fulminant hepatic failure therefore depends on a fine
balance between liver cell necrosis and regeneration, which in
turn depends on whether or not toxic substances injurious to
liver cells are eliminated.
Haemodialysis20 and haemofiltration21 are capable of remov-
ing toxic substances from the circulation but efficacy is low
becausemost toxic substances, such as bilirubin, endotoxin, and
cytokines are protein bound or large molecules. Plasmapheresis
is capable of removing these substances3 9 and when used in a
clinical trial, survival rates of 34% and 41% were recorded.22 23
However, elimination of the entire volume of the patient’s own
plasma means exhaustion of important biological factors that
could promote liver regeneration. This may explain why the
success rate of plasma exchange is not high.
Figure 6 Ki-67 immunohistochemical staining of a pig liver in the
AC-1770 group.
Figure 7 Ki-67 immunohistochemical staining of a pig liver in the
AC-1730 group.
Figure 8 Ki-67 immunohistochemical staining of a pig liver in the
plasma exchange group.
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In our present study, a selective plasma filter AC-1770 or
AC-1730 was added to the plasmapheresis circuit. AC-1770
and AC-1730 are cellulose diacetate membranes which are
characterised by sieving coefficients of approximately 0.85 and
0.7, respectively, for human albumin, approximately 0.7 and
0.3, respectively, for human IgG, and approximately 0.3 and
0.15, respectively, for IgM, according to the manufacturer’s
information. The pore size of the filters is efficient to filter the
protein bound toxins and retain large molecular weight
substances. TNF-α has a molecular weight of 17 kDa but could
be larger due to binding to proteins or mutimer forms24 25 in
plasma. As a result, its size is larger than 55 kDa but can still
be filtered through the AC-1770 or AC-1730 membrane. HGF
binding to heparin has a molecular weight of more than 200
kDa26 and is retained in the circulation. Based on the findings
of total protein, TNF-α, endotoxin, and other substances in the
filtrate, AC-1770 and AC-1730 probably fulfil the purpose of
selective elimination of unwanted substances. Of the two,
AC-1770 is perhaps a better choice based on laboratory results.
Plasma levels of TNF-α and endotoxin were not signifi-
cantly reduced after treatment or the next day. This was prob-
ably because constant release of TNF-α and endotoxin into the
circulation overwhelmed the function of the system. However,
it was found that similar clearance efficiencies of TNF-α were
obtained in the AC-1770 and AC-1730 groups compared with
that of the plasma exchange group. A longer duration of treat-
ment therefore may be necessary to reduce concentrations to
a significant level.
The additional benefit of selective plasma filtration was its
ability to retain a relatively large amount of HGF in the pig’s
circulation. As HGF is a potent mitogen for a variety of types
of epithelial cells, including hepatocytes,27 its higher retention
in the body would cause greater liver regeneration in pigs
treated by selective plasma filtration than that by plasma
exchange alone.
It has been shown that direct contact of peripheral blood
mononuclear cell with the filter membrane and adherence of
platelets to the membrane leads to complement activation and
cytokine production.28 In our experiments, after treatment
with selective plasma filtration, increased levels of TNF-α or
decreased platelet concentrations were not found. Indeed, the
biocompatibility of the membrane ensured low thrombogenic-
ity and low complement activation.29 The PF2000N plasma fil-
ter, AC-1770, and AC-1730 selective plasma filters are
currently used in clinical practice. Moreover, selective plasma
filtration did not induce hypocalcaemia as citrate was not used
as an anticoagulant. Instead, heparin was used to prevent
coagulation within the system. The use of heparin may be
advantageous in that HGF is bound to heparin forming a large
molecule and therefore is retained in the circulation.
Compared with other liver supporting systems, the draw-
back of selective plasma filtration is that it does not provide
liver function directly to the patient. The bioartificial liver
support system currently in clinical trials used porcine or
hepatoma cell lines to provide liver function. For porcine sup-
port systems, the risk and fear of transmission of endogenous
porcine retroviruses to humans have not been totally
eliminated.30 For selective plasma filtration to be applied in
clinical practice, the potential risk of transmission of
unknown viruses through fresh frozen plasma must be
excluded. However, this risk is low if all plasma is obtained
from a blood bank.
In conclusion, selective plasma filtration was beneficial in
halting liver injury and expediting liver regeneration. As the
complication rate related to plasmapheresis is less than 0.3%31
and addition of a filter membrane already in clinical use to the
plasmapheresis circuit may not cause problems, it should be
feasible to use selective plasma filtration in clinical trials to
determine its efficacy in patientswith fulminant hepatic failure.
. . . . . . . . . . . . . . . . . . . . .
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